Beijing Tiantan Biological Products Co., Ltd. (SHA:600161)
China
· Delayed Price · Currency is CNY 14.45
+0.09 (0.63%)
Apr 29, 2026, 3:00 PM CST
SHA:600161 Revenue
In the year 2025, Beijing Tiantan Biological Products had annual revenue of 6.17B CNY with 2.26% growth. Beijing Tiantan Biological Products had revenue of 1.70B in the quarter ending December 31, 2025, a decrease of -13.05%.
Revenue
6.17B
Revenue Growth
+2.26%
P/S Ratio
4.60
Revenue / Employee
1.19M
Employees
5,205
Market Cap
28.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.17B | 136.17M | 2.26% |
| Dec 31, 2024 | 6.03B | 851.42M | 16.44% |
| Dec 31, 2023 | 5.18B | 919.14M | 21.57% |
| Dec 31, 2022 | 4.26B | 149.15M | 3.63% |
| Dec 31, 2021 | 4.11B | 666.56M | 19.35% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hualan Biological Engineering | 4.49B |
| Suzhou Zelgen Biopharmaceuticals | 810.48M |
| BrightGene Bio-Medical Technology | 1.22B |
| Xiamen Amoytop Biotech | 3.70B |
| Chongqing Zhifei Biological Products | 8.75B |
| Hebei Changshan Biochemical Pharmaceutical | 872.53M |
| Shanghai RAAS Blood Products | 7.35B |
| Yili Chuanning Biotechnology | 4.41B |